All studies | CD30+ specified

Recurrent

All studies

Newly diagnosed or untreated

Recurrent

All studies

All studies

Newly diagnosed or untreated

Recurrent 

All studies

Newly diagnosed or untreated

Recurrent

Rituxan (by request)

Rituxan without chemotherapy (by request)

All Studies

All Studies

Newly diagnosed or untreated

Recurrent

All studies

DLBCL and Radioimmunotherapy

With CNS involvement

Newly diagnosed or untreated 

Recurrent

All studies 

All studies | Small Cleaved | Large cell | Mixed Cell

All newly diagnosed or untreated - Small cleaved | Large cell | Mixed cell

All recurrent - Small cleaved | Large cell | Mixed cell

All studies

Newly diagnosed or untreated

Recurrent | Lymphocyte predominant

All studies

Newly diagnosed or untreated (fixed 11-18)

Recurrent

All studies

Bexxar regimens

Newly Diagnosed or untreated 

Recurrent

All studies

Newly diagnosed or untreated | including adult NHL unspecified

Recurrent 

MDS (Myelodysplastic Syndrome) - 
a complication of treatment for lymphoma

All treatments (check for aliases - too few results)

All studies

Newly diagnosed or untreated

Recurrent

Anaplastic Large Cell type: 
Newly diagnosed or  previously untreated  AND Recurrent

Angioimmunoblastic type | with stem cell transplant

NK Cell 

PTCL (Peripheral T-cell Lymphoma) 

Anti-Tac  for Tac-expressing NHL, including T-cell NHL)

Daclizumab (t-cell lymphomas)

Denileukin diftitox - ONTAK 
(IL-2/diphtheria toxin fusion protein)

Possible mechanisms: "The IL-2 portion of the molecule targets the lymphoma cells by binding to the IL-2 receptor on the plasma membrane, and upon endocytosis, the diphtheria toxin is delivered to the lymphoma cells. Common side effects are nausea and vomiting, fever and flu-like symptoms. Other significant side effects include the cytokine release syndrome and vascular leak syndrome"-  ncbi.nlm.nih.gov/books

Topic Search on this agent: PubMed

Depsipeptide (histone deacetylase inhibitor)

Possible mechanisms: induction of apoptosis, cell cycle arrest, and differentiation via the modulation of gene expression by histone acetylation

Topic Search on this agent: PubMed

Immune therapies

Pralatrexate  

Possible mechanisms: "Pralatrexate is a novel antifolate designed to have high affinity for the reduced folate carrier type 1 (RFC-1). Preclinical and clinical studies have demonstrated that pralatrexate has significant activity against TCL." - PMID: 16988580

Topic Search on this agent: PubMed

Radioimmunotherapy 

SAHA (Suberoylanilide Hydroxamic Acid)
  
Possible mechanisms: "SAHA treatment caused an accumulation of acetylated histones (H2B, H3, and H4), an increase of p21(WAF1) and bax proteins, a decrease of Stat6 and phospho-Stat6 proteins, and activation of caspase-3 in CTCL cells." - PMID: 16297208

Topic Search on this agent: PubMed

T-cell antibodies  (biological agents that bind to receptors expressed on t-cells)

All studies 

CLL (transformed Chronic Lymphocytic Lymphoma/Leukemia)

Follicular

Radioimmunotherapy

All studies

newly diagnosed or untreated

recurrent